Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration has approved the company’s oncology drug, Nelarabine Injection, ...

To our shareholders and supporters, thank you again for your continued confidence and long-term support. We are committed to ...

Euan Ashley's lab explores the intricate interactions of gene variants. Tiny "typos," or genetic mutations, can sneak into ...

In the Challenger shuttle tragedy 40 years ago this week, two technologies – aerospace and television – flexed their muscles ...

Omni NDE cobots, X-ray end effectors and Voxray’s reconstruction approach enables 5-micron inspection of aerospace parts ...

Scientists have discovered a molecule that shrinks brain tumors in mice, raising hopes that the compound could one day become a pill to treat glioblastoma, one of the world’s most pernicious cancers.

As cold as the January weather has been, the December warm weather was more extreme.  The recent lows in the mid teens don’t ...

REGENXBIO Inc.  today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler ...

Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting - ...

Enveric Biosciences, Inc. ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today ...

Wafer breakage is the most serious impact of killer crystalline defects. About 0.1 to 0.2% of silicon wafers break. The ...

Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting - - Final ...